About InVivoSIM anti-human CD3 x BCMA (Teclistamab Biosimilar) This non-therapeutic biosimilar antibody utilizes the same variable regions as the therapeutic antibody Teclistamab, making it ideal for research use. Teclistamab is a humanized IgG4 bispecific monoclonal antibody that targets both B-cell maturation antigen (BCMA) on malignant plasma cells and CD3ε on T cells. BCMA is predominantly expressed on plasma cells and plays a crucial role in their survival and proliferation. By simultaneously binding to BCMA and CD3, Teclistamab redirects T cells to recognize and eliminate BCMA-expressing multiple myeloma cells through T-cell activation and subsequent cytotoxicity. The Fc region of Teclistamab contains S228P/L234A/L235A mutations to minimize its immunological effector functions. This biosimilar antibody is a valuable tool for studying T-cell engagement, bispecific antibody mechanisms, and BCMA-targeted therapies. InVivoSIM anti-human CD3 x BCMA (Teclistamab Biosimilar) Specifications IsotypeHuman IgG4, λ Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman BCMA-Fc recombinant protein Reported ApplicationsFunctional assays Flow cytometry ELISA Immunohistochemistry FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
